Replies to post #179213 on Biotech Values

[frontiers]

all serious HCV players knew that IDIX was on the block and MRK disclosed that it performed animal testing on IDIX’s nuke in combination with MRK’s PI and NS5A

Yes, this is true. IDIX has been known to be on the block. And Merck did make the disclosure you noted.

There has been no news reported that ACHN is on the block (that I know of). They have always contended that that they have all three parts of a HCV cure -- a PI (2684, 1625), a NS5A-I (3102), and a NS5B-I (3422) and planned to develop an in-house combo.

Of course, they will consider a buy-out deal at the right price. But its too early for that.

So I'm not sure if 3422 has been evaluated in-house by any outside parties.